ACO 253

Drug Profile

ACO 253

Alternative Names: AC 253; Antam; GG 747; GR 1150747A

Latest Information Update: 24 Feb 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amylin Pharmaceuticals
  • Class Antihyperglycaemics
  • Mechanism of Action Islet amyloid polypeptide inhibitors; Islet amyloid polypeptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 24 Feb 1997 Discontinued-I for Obesity in USA (Unknown route)
  • 24 Feb 1997 Discontinued-I for Type-2 diabetes mellitus in USA (SC)
  • 13 Nov 1995 Phase-I clinical trials for Obesity in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top